Arovella Therapeutics Ltd Gets Ethics Approval for First Human Blood Cancer Trial
Ethics approval clears final hurdle for Arovella’s first-in-human cancer trial
Arovella Therapeutics (ASX: ALA) has received ethics approval to commence its Phase 1 first-in-human clinical trial of lead therapy ALA-101, an allogeneic CAR-iNKT cell therapy for patients with blood cancer.
The approval completes the key regulatory and ethics requirements needed to initiate the study, following earlier US FDA Investigational New Drug (IND) clearance and Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) acknowledgement.
First patient dosing is expected in Q3 CY2026 (September 2026), subject to each clinical site’s Research Governance Office (RGO) approval. The trial targets patients with relapsed or refractory lymphomas and leukemias, marking Arovella’s transition from pre-clinical to clinical-stage.
When big ASX news breaks, our subscribers know first
What the approval covers and where the trial will run
The Phase 1 trial is an open label, first-in-human dose-escalation and expansion/backfill study designed to evaluate the safety, tolerability and preliminary anti-tumour activity of ALA-101 in patients with certain blood cancers.
The Alfred in Melbourne serves as the lead clinical site, with experienced CAR-T cell therapy clinician Dr Salvatore “Sam” Fiorenza appointed as Lead Investigator. Ethics approval has been obtained from The Alfred and Bellberry Human Research Ethics Committees, providing central ethics support for participating study sites.
The trial is expected to involve up to seven clinical sites across Australia and New Zealand, with site activation activities underway at the following locations:
-
The Alfred, Melbourne (lead site)
-
Epworth Healthcare
-
St Vincent’s Sydney
-
The Mater Brisbane
-
Royal Adelaide Hospital
Dr Sam Fiorenza, Lead Investigator
“There is a substantial unmet need for patients with relapsed or refractory haematological cancers, particularly for patients who have exhausted existing treatment options. As clinician researchers, finding novel therapies that will result in better outcomes for our patients is the hope, and we are pleased to be part of the evaluation of this new approach.”
The regulatory pathway: how Arovella reached first-in-human
The ethics approval represents the final step in a sequence of completed regulatory and ethics milestones, reflecting what management has described as a disciplined approach to clinical readiness. The table below summarises the progression toward first patient dosing.
FDA IND acceptance for ALA-101 represented the first major regulatory checkpoint in this sequence, with the US clearance validating Arovella’s development programme and establishing the framework subsequently applied to its Australian regulatory pathway.
| Regulatory/Ethics Milestone | Authority | Status |
|---|---|---|
| IND application | US FDA | Cleared |
| Clinical Trial Notification (CTN) | TGA | Acknowledged |
| Ethics approval | The Alfred & Bellberry HRECs | Obtained |
| Site initiation | RGO (per site) | Underway |
| First patient dosing | — | Expected Q3 CY2026 |
Dr Nicole van der Weerden, Acting CEO
“First-in-human is an important step in our transition to a clinical-stage company and is the culmination of the disciplined approach we have taken in regulatory, manufacturing and clinical readiness. We are preparing to complete site initiation and first patient dosing. This milestone means we can evaluate the potential of our allogeneic CAR-iNKT platform for patients with significant unmet medical need and generate clinical data important for patients, clinicians and shareholders. I anticipate exciting and important data to come from this trial.”
What is an allogeneic CAR-iNKT cell therapy?
For readers less familiar with cell therapy, ALA-101 is built on a design that aims to broaden how these treatments can be delivered. The therapy is described as allogeneic, or “off-the-shelf,” which means it can be given from a healthy donor to a patient. This contrasts with patient-specific approaches that require cells to be taken from the individual being treated.
ALA-101 consists of CAR19-iNKT cells, which are modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19, an antigen found on the surface of numerous cancer types. The therapy also features a dual-targeting characteristic. The iNKT cells contain an invariant T cell receptor (iTCR) that targets glycolipid-bound CD1d, another antigen found on several cancer types.
The underlying iNKT cell therapy platform is licensed from Imperial College London.
The next major ASX story will hit our subscribers first
Why this milestone matters for investors
The clearance positions Arovella to generate its first human data from the ALA-101 platform. The transition to a clinical-stage company is widely regarded by biotech investors as a key inflection point.
Beyond the lead programme, Arovella retains broader platform optionality at an early stage. The company is expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group, and intends to incorporate its IL-12-TM technology into its solid tumour programmes.
CLDN18.2-targeting technology in preclinical testing has demonstrated tumour kill rates exceeding 97% in pancreatic cancer cell lines, with the IL-12-TM armouring component sustaining tumour destruction across all four rounds of a serial challenge assay.
David Williams, Chairman
“First-in-human cannot happen fast enough for me because there is a long list of patients with nowhere else to go.”
With the regulatory and ethics framework now complete, Arovella remains on track to commence first patient dosing in Q3 CY2026, with clinical data anticipated to follow.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next major biotech milestone the moment it drops.